Skip to main content
Top
Published in: Archives of Dermatological Research 6/2010

Open Access 01-08-2010 | Original Paper

Ichthyosis in Sjögren–Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion

Authors: William B. Rizzo, Dana S’Aulis, M. Anitia Jennings, Debra A. Crumrine, Mary L. Williams, Peter M. Elias

Published in: Archives of Dermatological Research | Issue 6/2010

Login to get access

Abstract

Sjögren–Larsson syndrome is a genetic disease characterized by ichthyosis, mental retardation, spasticity and mutations in the ALDH3A2 gene coding for fatty aldehyde dehydrogenase, an enzyme necessary for oxidation of fatty aldehydes and fatty alcohols. We investigated the cutaneous abnormalities in 9 patients with Sjögren–Larsson syndrome to better understand how the enzymatic deficiency results in epidermal dysfunction. Histochemical staining for aldehyde oxidizing activity was profoundly reduced in the epidermis. Colloidal lanthanum perfusion studies showed abnormal movement of tracer into the extracellular spaces of the stratum corneum consistent with a leaky water barrier. The barrier defect could be attributed to the presence of abnormal lamellar bodies, many with disrupted limiting membranes or lacking lamellar contents. Entombed lamellar bodies were present in the cytoplasm of corneocytes suggesting blockade of lamellar body secretion. At the stratum granulosum–stratum corneum interface, non-lamellar material displaced or replaced secreted lamellar membranes, and in the stratum corneum, the number of lamellar bilayers declined and lamellar membrane organization was disrupted by foci of lamellar/non-lamellar phase separation. These studies demonstrate the presence of a permeability barrier abnormality in Sjögren–Larsson syndrome, which localizes to the stratum corneum interstices and can be attributed to abnormalities in lamellar body formation and secretion.
Literature
1.
go back to reference Brash AR, Yu Z, Boeglin WE, Schneider C (2007) The hepoxilin connection in the epidermis. FEBS J 274:3494–3502CrossRefPubMed Brash AR, Yu Z, Boeglin WE, Schneider C (2007) The hepoxilin connection in the epidermis. FEBS J 274:3494–3502CrossRefPubMed
2.
go back to reference De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, Markova N, Rizzo WB (1996) Sjögren–Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 12:52–57CrossRefPubMed De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, Markova N, Rizzo WB (1996) Sjögren–Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 12:52–57CrossRefPubMed
3.
go back to reference Demerjian M, Crumrine DA, Milstone LM, Williams ML, Elias PM (2006) Barrier dysfunction and pathogenesis of neutral lipid storage disease with ichthyosis (Chanarin–Dorfman syndrome). J Invest Dermatol 126:2032–2038CrossRefPubMed Demerjian M, Crumrine DA, Milstone LM, Williams ML, Elias PM (2006) Barrier dysfunction and pathogenesis of neutral lipid storage disease with ichthyosis (Chanarin–Dorfman syndrome). J Invest Dermatol 126:2032–2038CrossRefPubMed
4.
go back to reference Elias PM (1983) Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 80(Suppl):44s–49sCrossRef Elias PM (1983) Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 80(Suppl):44s–49sCrossRef
5.
go back to reference Elias PM, Cullander C, Maura T, Rassner U, Kömüves L, Brown BE, Menon GK (1998) The secretory granular cell: the outermost granular cell as a specialized secretory cell. J Invest Dermatol Symp Proc 3:87–100 Elias PM, Cullander C, Maura T, Rassner U, Kömüves L, Brown BE, Menon GK (1998) The secretory granular cell: the outermost granular cell as a specialized secretory cell. J Invest Dermatol Symp Proc 3:87–100
6.
go back to reference Elias PM, Menon GK (1991) Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 24:1–26PubMed Elias PM, Menon GK (1991) Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 24:1–26PubMed
7.
go back to reference Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M (2008) Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 49:697–714CrossRefPubMed Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M (2008) Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 49:697–714CrossRefPubMed
8.
go back to reference Feingold KR, Man MQ, Proksch E, Menon GK, Brown BE, Elias PM (1991) The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia. J Invest Dermatol 96:201–209CrossRefPubMed Feingold KR, Man MQ, Proksch E, Menon GK, Brown BE, Elias PM (1991) The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia. J Invest Dermatol 96:201–209CrossRefPubMed
9.
go back to reference Hanley K, Kömüves LG, Ng DC, Schoonjans K, He SS, Lau P, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR (2000) Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 275:11484–11491CrossRefPubMed Hanley K, Kömüves LG, Ng DC, Schoonjans K, He SS, Lau P, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR (2000) Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 275:11484–11491CrossRefPubMed
10.
go back to reference Hinson DD, Chambliss KL, Toth MJ, Tanaka RD, Gibson KM (1997) Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J Lipid Res 38:2216–2223PubMed Hinson DD, Chambliss KL, Toth MJ, Tanaka RD, Gibson KM (1997) Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J Lipid Res 38:2216–2223PubMed
11.
go back to reference Ito M, Oguro K, Sato Y (1991) Ultrastructural study of the skin in Sjögren–Larsson syndrome. Arch Dermatol Res 283:141–148CrossRefPubMed Ito M, Oguro K, Sato Y (1991) Ultrastructural study of the skin in Sjögren–Larsson syndrome. Arch Dermatol Res 283:141–148CrossRefPubMed
12.
go back to reference Jagell S, Heijbel J (1982) Sjögren–Larsson syndrome: physical and neurological features. A survey of 35 patients. Helv Paediatr Acta 37:519–530PubMed Jagell S, Heijbel J (1982) Sjögren–Larsson syndrome: physical and neurological features. A survey of 35 patients. Helv Paediatr Acta 37:519–530PubMed
13.
14.
go back to reference James PF, Zoeller RA (1997) Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff’s base modification of phospholipids: implications for Sjögren–Larsson syndrome. J Biol Chem 272:23532–23539CrossRefPubMed James PF, Zoeller RA (1997) Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. Sensitivity to fatty aldehydes and Schiff’s base modification of phospholipids: implications for Sjögren–Larsson syndrome. J Biol Chem 272:23532–23539CrossRefPubMed
15.
go back to reference Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, Ozgüc M, Lathrop M, Prud’homme JF, Fischer J (2002) Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 11:107–113CrossRefPubMed Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, Ozgüc M, Lathrop M, Prud’homme JF, Fischer J (2002) Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 11:107–113CrossRefPubMed
16.
go back to reference Judge MR, Lake BD, Smith VV, Besley GT, Harper JI (1990) Depletion of alcohol (hexanol) dehydrogenase activity in the epidermis and jejunal mucosa in Sjögren–Larsson syndrome. J Invest Dermatol 95:632–634CrossRefPubMed Judge MR, Lake BD, Smith VV, Besley GT, Harper JI (1990) Depletion of alcohol (hexanol) dehydrogenase activity in the epidermis and jejunal mucosa in Sjögren–Larsson syndrome. J Invest Dermatol 95:632–634CrossRefPubMed
17.
go back to reference Kelson TL, Secor M Jr, Rizzo WB (1997) Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochim Biophys Acta 1335:99–110PubMed Kelson TL, Secor M Jr, Rizzo WB (1997) Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochim Biophys Acta 1335:99–110PubMed
18.
go back to reference Lefevre C, Bouadjar B, Ferrand V, Tadini G, Megarbane A, Lathrop M, Prud’homme JF, Fischer J et al (2006) Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 15:767–776CrossRefPubMed Lefevre C, Bouadjar B, Ferrand V, Tadini G, Megarbane A, Lathrop M, Prud’homme JF, Fischer J et al (2006) Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 15:767–776CrossRefPubMed
19.
go back to reference Lefevre C, Bouadjar B, Karaduman A, Jobard F, Saker S, Ozguc M, Lathrop M, Prud’homme JF, Fischer J (2004) Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet 13:2473–2482CrossRefPubMed Lefevre C, Bouadjar B, Karaduman A, Jobard F, Saker S, Ozguc M, Lathrop M, Prud’homme JF, Fischer J (2004) Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet 13:2473–2482CrossRefPubMed
20.
go back to reference Levisohn D, Dintiman B, Rizzo WB (1991) Sjögren–Larsson syndrome. Case reports. Pediatr Dermatol 8:217–220CrossRefPubMed Levisohn D, Dintiman B, Rizzo WB (1991) Sjögren–Larsson syndrome. Case reports. Pediatr Dermatol 8:217–220CrossRefPubMed
22.
go back to reference Madison KC (2003) Barrier function of the skin: “la raison d’etre” of the epidermis. J Invest Dermatol 121:231–241CrossRefPubMed Madison KC (2003) Barrier function of the skin: “la raison d’etre” of the epidermis. J Invest Dermatol 121:231–241CrossRefPubMed
23.
go back to reference Matsuoka LY, Kousseff BG, Hashimoto K (1982) Studies of the skin in Sjögren–Larsson syndrome by electron microscopy. Am J Dermatopathol 4:295–301CrossRefPubMed Matsuoka LY, Kousseff BG, Hashimoto K (1982) Studies of the skin in Sjögren–Larsson syndrome by electron microscopy. Am J Dermatopathol 4:295–301CrossRefPubMed
24.
go back to reference Meigs TE, Roseman DS, Simoni RD (1996) Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 271:7916–7922CrossRefPubMed Meigs TE, Roseman DS, Simoni RD (1996) Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J Biol Chem 271:7916–7922CrossRefPubMed
25.
go back to reference Menon GK, Feingold KR, Mao-Qiang M, Schaude M, Elias PM (1992) Structural basis for the barrier abnormality following inhibition of HMG CoA reductase in murine epidermis. J Invest Dermatol 98:209–219CrossRefPubMed Menon GK, Feingold KR, Mao-Qiang M, Schaude M, Elias PM (1992) Structural basis for the barrier abnormality following inhibition of HMG CoA reductase in murine epidermis. J Invest Dermatol 98:209–219CrossRefPubMed
26.
go back to reference Rizzo WB (2001) Sjögren–Larsson syndrome: fatty aldehyde dehydrogenase deficiency. In: Scriver CR, Beckman K, Small GM, Valle D (eds) The metabolic & molecular bases of inherited disease, vol 2. McGraw-Hill, New York, pp 2239–2258 Rizzo WB (2001) Sjögren–Larsson syndrome: fatty aldehyde dehydrogenase deficiency. In: Scriver CR, Beckman K, Small GM, Valle D (eds) The metabolic & molecular bases of inherited disease, vol 2. McGraw-Hill, New York, pp 2239–2258
27.
go back to reference Rizzo WB (2007) Sjögren–Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab 90:1–9CrossRefPubMed Rizzo WB (2007) Sjögren–Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab 90:1–9CrossRefPubMed
28.
go back to reference Rizzo WB, Carney G, Lin Z (1999) The molecular basis of Sjögren–Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet 65:1547–1560CrossRefPubMed Rizzo WB, Carney G, Lin Z (1999) The molecular basis of Sjögren–Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet 65:1547–1560CrossRefPubMed
29.
go back to reference Rizzo WB, Craft DA (1991) Sjögren–Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol: NAD+ oxidoreductase in cultured fibroblasts. J Clin Invest 88:1643–1648CrossRefPubMed Rizzo WB, Craft DA (1991) Sjögren–Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol: NAD+ oxidoreductase in cultured fibroblasts. J Clin Invest 88:1643–1648CrossRefPubMed
30.
go back to reference Rizzo WB, Craft DA (2000) Sjögren–Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J Lipid Res 41:1077–1081PubMed Rizzo WB, Craft DA (2000) Sjögren–Larsson syndrome: accumulation of free fatty alcohols in cultured fibroblasts and plasma. J Lipid Res 41:1077–1081PubMed
31.
go back to reference Rizzo WB, Craft DA, Somer T, Carney G, Trafrova J, Simon M (2008) Abnormal fatty alcohol metabolism in cultured keratinocytes from patients with Sjögren–Larsson syndrome. J Lipid Res 49:410–419CrossRefPubMed Rizzo WB, Craft DA, Somer T, Carney G, Trafrova J, Simon M (2008) Abnormal fatty alcohol metabolism in cultured keratinocytes from patients with Sjögren–Larsson syndrome. J Lipid Res 49:410–419CrossRefPubMed
32.
go back to reference Sanders RJ, Ofman R, Dacremont G, Wanders RJ, Kemp S (2008) Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids. FASEB J 22:2064–2071CrossRefPubMed Sanders RJ, Ofman R, Dacremont G, Wanders RJ, Kemp S (2008) Characterization of the human omega-oxidation pathway for omega-hydroxy-very-long-chain fatty acids. FASEB J 22:2064–2071CrossRefPubMed
33.
go back to reference Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, Rappersberger K, Crumrine D, Feingold KR, Elias PM (2001) Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol 117:837–847CrossRefPubMed Schmuth M, Yosipovitch G, Williams ML, Weber F, Hintner H, Ortiz-Urda S, Rappersberger K, Crumrine D, Feingold KR, Elias PM (2001) Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol 117:837–847CrossRefPubMed
34.
go back to reference Shibaki A, Akiyama M, Shimizu H (2004) Novel ALDH3A2 heterozygous mutations are associated with defective lamellar granule formation in a Japanese family of Sjögren–Larsson syndrome. J Invest Dermatol 123:1197–1199CrossRefPubMed Shibaki A, Akiyama M, Shimizu H (2004) Novel ALDH3A2 heterozygous mutations are associated with defective lamellar granule formation in a Japanese family of Sjögren–Larsson syndrome. J Invest Dermatol 123:1197–1199CrossRefPubMed
35.
go back to reference Sjögren T, Larsson T (1957) Oligophrenia in combination with congenital ichthyosis and spastic disorders. Acta Psychiatr Neurol Scand 32(Suppl 113):1–113 Sjögren T, Larsson T (1957) Oligophrenia in combination with congenital ichthyosis and spastic disorders. Acta Psychiatr Neurol Scand 32(Suppl 113):1–113
36.
go back to reference van Domburg PHMF, Willemsen MAAP, Rotteveel JJ, de Jong JG, Thijssen HOM, Heerschap A, Cruysberg JRM, Wanders RJA, Gabreëls FJM, Steijlen PM (1999) Sjögren–Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients. Neurology 52:1345–1352PubMed van Domburg PHMF, Willemsen MAAP, Rotteveel JJ, de Jong JG, Thijssen HOM, Heerschap A, Cruysberg JRM, Wanders RJA, Gabreëls FJM, Steijlen PM (1999) Sjögren–Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients. Neurology 52:1345–1352PubMed
37.
go back to reference Willemsen MAAP, Cruysberg JRM, Rotteveel JJ, Aandekerk AL, van Domburg PHMF, Deutman AF (2000) Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren–Larsson syndrome. Am J Ophthalmol 130:782–789CrossRefPubMed Willemsen MAAP, Cruysberg JRM, Rotteveel JJ, Aandekerk AL, van Domburg PHMF, Deutman AF (2000) Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjögren–Larsson syndrome. Am J Ophthalmol 130:782–789CrossRefPubMed
38.
go back to reference Willemsen MAAP, Lutt MA, Steijlen PM, Cruysberg JR, van der Graaf M, Nijhuis-van der Sanden MW, Pasman JW, Mayatepek E, Rotteveel JJ (2001) Clinical and biochemical effects of zileuton in patients with the Sjögren–Larsson syndrome. Eur J Pediatr 160:711–717PubMed Willemsen MAAP, Lutt MA, Steijlen PM, Cruysberg JR, van der Graaf M, Nijhuis-van der Sanden MW, Pasman JW, Mayatepek E, Rotteveel JJ (2001) Clinical and biochemical effects of zileuton in patients with the Sjögren–Larsson syndrome. Eur J Pediatr 160:711–717PubMed
39.
go back to reference Willemsen MAAP, Rotteveel JJ, de Jong JG, Wanders RJA, Ijlst L, Hoffmann GFM, Mayatepek E (2001) Defective metabolism of leukotriene B4 in the Sjögren–Larsson syndrome. J Neurol Sci 183:61–67CrossRefPubMed Willemsen MAAP, Rotteveel JJ, de Jong JG, Wanders RJA, Ijlst L, Hoffmann GFM, Mayatepek E (2001) Defective metabolism of leukotriene B4 in the Sjögren–Larsson syndrome. J Neurol Sci 183:61–67CrossRefPubMed
40.
go back to reference Willemsen MAAP, van der Graaf M, van der Knaap MS, Heerschap A, van Domburg PHMF, Gabreels FJ, Rotteveel JJ (2004) MR imaging and proton MR spectroscopic studies in Sjögren–Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 25:649–657PubMed Willemsen MAAP, van der Graaf M, van der Knaap MS, Heerschap A, van Domburg PHMF, Gabreels FJ, Rotteveel JJ (2004) MR imaging and proton MR spectroscopic studies in Sjögren–Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 25:649–657PubMed
Metadata
Title
Ichthyosis in Sjögren–Larsson syndrome reflects defective barrier function due to abnormal lamellar body structure and secretion
Authors
William B. Rizzo
Dana S’Aulis
M. Anitia Jennings
Debra A. Crumrine
Mary L. Williams
Peter M. Elias
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Archives of Dermatological Research / Issue 6/2010
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-009-1022-y

Other articles of this Issue 6/2010

Archives of Dermatological Research 6/2010 Go to the issue